Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 11, 1995, Pages 1938-1944

  Shiomi, Masashi ^a   Ito, Takashi ^a   Tsukada, Toyohiro ^b   Yata, Tatsuo ^a   Watanabe, Yoshio ^a   Tsujita, Yoshio ^b   Fukami, Masaharu ^b   Fukushige, Jun Ichiro ^b   Hosokawa, Tsunemichi ^b   Tamura, Atsuhiro ^b  

^a KOBE UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

atherosclerosis; cholesterol reduction; macrophages; smooth muscle cells; WHHL rabbit

Indexed keywords

HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0028853846     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.15.11.1938     Document Type: Article

References (36)

1. Kimura J, Nakagami K, Amanuma K, Ohkuma S, Yoshida Y, Takano T. Monoclonal antibodies recognizing lipid-laden cells and extracellular regions with lipid-deposits in atherosclerotic aorta. Virchows Arch A Pathol Anat Histopathol. 1986;410:159-164.
2. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215-218.
3. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Bulter SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
4. Tanzawa K, Shimada Y, Kuroda M, Tsujita Y, Arai M, Watanabe Y. WHHL rabbit: a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia. FEBS Lett. 1980; 118:81-84.
5. Kita T, Brown MS, Watanabe Y, Goldstein JL. Deficiency of low density lipoprotein receptor in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1981;78:2268-2272.
6. Shiomi M, Ito T, Watanabe Y. Increase in hepatic low density lipoprotein receptor activity during pregnancy in Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model for familial hypercholesterolemia. Biochim Biophys Acta. 1987;917: 92-100.
7. Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y, Fujii S. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986;877:50-60.
8. Watanabe Y, Ito T, Shiomi M, Tsujita Y, Kuroda M, Arai M, Fukami M, Tamura A. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta. 1988;960:294-302.
9. Kuroda M, Matsumoto A, Itakura H, Watanabe Y, Ito T, Shiomi M, Fukushige J, Nara F, Fukami M, Taujita Y. Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits. Jpn J Pharmacol. 1992;59:65-70.
10. Shiomi M, Ito T. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits. Metabolism. 1994;43:S59-564.
11. Shiomi M, Ito T, Watanabe Y, Tsujita Y, Kuroda M, Arai M, Fukami M, Fukushige J, Tamura A. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Atherosclerosis. 1990;83:69-80.
12. Tsukada T, Tippens D, Gordon D, Ross R, Gown AM. HHF35, a muscle-actin-specific monoclonal antibody, I: immunocytochemical and biomedical characterization. Am J Pathol. 1987;126:51-69.
13. Tsukada T, Rosenfeld ME, Ross R, Gown AM. Immunocytochemical analysis of cellular components in atherosclerotic lesions: use of monoclonal antibodies with Watanabe and fat-fed rabbit. Arteriosclerosis. 1986;6:601-613.
14. Rosenfeld ME, Tsukada T, Gown AM, Ross R. Fatty streak initiation in Watanabe heritable hyperlipidemic and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis. 1987;7:9-23.
15. Rosenfeld ME, Tsukada T, Chait A, Bierman EL, Gown AM, Ross R. Fatty streak expansion and maturation in Watanabe heritable hyperlipidemic and comparably hyperlipidemic fat-fed rabbits. Arteriosclerosis. 1987;7:24-34.
16. Ito T, Tsukada T, Ueda M, Wanibuchi H, Shiomi M. Immunohistochemical and quantitative analysis of cellular and extracellular components of aortic atherosclerosis in WHHL rabbits. J Atheroscler Thromb. 1994;1:45-52.
17. Shiomi M, Ito T, Tsukada T, Yata T, Ueda M. Cell composition of coronary and aortic atherosclerotic lesions in WHHL rabbits differs: an immunohistochemical study. Arterioscler Thromb. 1994; 14:931-937.
18. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effect of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72: 1031-1037.
19. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol. 1993;73:1133-1134.
20. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
21. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
22. MAAS Investigators. Effect of Simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet. 1994;344: 633-638.
23. Brown GB, Zhao XQ, Sacco DE, Albers KK. Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. Br Heart J. 1993;69(suppl):S48-S53.
24. Shiomi M, Ito T, Shiraishi M, Watanabe Y. Inheritability of atherosclerosis and the role of lipoproteins as risk factors in the development of atherosclerosis in WHHL rabbits: risk factors related to coronary atherosclerosis are different from those related to aortic atherosclerosis. Atherosclerosis. 1992;96:43-52.
25. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
26. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl II): II-3-II-16.
27. Mitchinson MS, Ball RV. Macrophages and atherosclerosis. Lancet. 1982;2:146-147.
28. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
29. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
30. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
31. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res. 1983;24:1070-1076.
32. Jimi S, Sakata N, Takebayashi S. Oxidized LDL induces an increase in the relative collagen synthesis of rabbit aortic smooth muscle cells. J Atherosder Thromb. 1994;1:53-59.
33. Kume N, Cybulski MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138-1144.
34. Parthasarathy S, Printz DJ, Boyd D, Joy L, Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by scavenger receptor. Arteriosclerosis. 1986;6: 505-510.
35. Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem. 1989;264:2599-2604.
36. Dejager S, Mietus-Sneider M, Pitas RE. Oxidized low density lipoproteins bind to the scavenger receptor expressed by rabbit smooth muscle cells and macrophages. Arterioscler Thromb. 1993; 13:372-378.